Table II.

Comparison between Baseline and Follow-up Measures in Follow-Up Participants.

	Baseline	Follow-up	Significance
Age, mean ± SD	13.7 ± 2.8	16.4 ± 3.1
NIMH-TSS	10.4 ± 3.5	8.7 ± 4.4	0.46
MGH-HPS	11.4 ± 5.6	11.8 ± 5.7	0.77
TSC-C	1.9 ± 0.7	2.0 ± 0.8	0.52
TSC-P	1.8 ± 0.7	1.7 ± 0.8	0.89
MIST-Automatic Subscale	13.5 ± 7.3	11.4 ± 5.9	0.045
MIST-Focused Subscale	90.9 ± 29.4	91.3 ± 36.8	0.94
CDI	8.1 ± 7.5	15.2 ± 12.0	0.0001
MASC	48.1 ± 16.6	54.1 ± 18.4	0.009
# Pulling Sites	1.7 ± 0.9	1.5 ± 1.0	0.22
Treatment, current (n (%))
Antidepressants	15 (50%)	9 (30%)	0.19
Antipsychotic agents	2 (7%)	2 (7%)	1
NAC	18 (60%)*	0	<0.0001
Behavioral Therapy	9 (30%)	5 (18%)	0.36

The primary analyses are from the end of the acute phase in the NAC trial.

Abbreviations: NIMH-TSS, National Institute of Mental Health – Trichotillomania Severity Scale; MGH-HPS, Massachusetts General Hospital – Hairpulling Scale; TSC-C,P, Trichotillomania Scale for Children – Child and Parent Versions; MIST, Milwaukee Inventory for Styles of Trichotillomania; CDI, Children’s Depression Inventory; MASC, Multidimensional Anxiety Scale for Children; NAC, N- Acetylcysteine.

^*All children who did not receive NAC during the double-blind phase of the trial, received NAC treatment during the follow-up period but decided to discontinue it.